Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Experience with intermediate-dose (110-120 mg/m2) epirubicin.

T Hickish1, D Cunningham, A Haydock

  • 1St. George's Hospital, London.

Cancer Chemotherapy and Pharmacology
|January 1, 1989
PubMed
Summary

Epirubicin chemotherapy showed promising activity in advanced cancers, including gastric, breast, and sarcoma. Doses up to 120 mg/m2 were generally tolerated, though mucositis increased significantly at the highest dose.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quality assurance of surgery in the randomized ST03 trial of perioperative chemotherapy in carcinoma of the stomach and gastro-oesophageal junction.

The British journal of surgery·2019
Same author

Patient-level costs in margin re-excision for breast-conserving surgery.

The British journal of surgery·2018
Same author

A seven-Gene Signature assay improves prognostic risk stratification of perioperative chemotherapy treated gastroesophageal cancer patients from the MAGIC trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Third line treatment of advanced oesophagogastric cancer: A critical review of current evidence and evolving trends.

Cancer treatment reviews·2018
Same author

Neoadjuvant rectal score: run with the hare and hunt with the hounds.

Annals of oncology : official journal of the European Society for Medical Oncology·2018
Same author

Lymph node regression and survival following neoadjuvant chemotherapy in oesophageal adenocarcinoma.

The British journal of surgery·2018

Area of Science:

  • Oncology
  • Pharmacology
  • Clinical Trials

Background:

  • Advanced malignancies pose significant treatment challenges.
  • Epirubicin is an anthracycline chemotherapy agent used in various cancers.
  • Understanding dose-limiting toxicities and efficacy is crucial for optimizing cancer treatment.

Purpose of the Study:

  • To evaluate the safety and efficacy of escalating doses of epirubicin in patients with advanced malignancies.
  • To identify dose-limiting toxicities associated with epirubicin administration.
  • To explore preliminary antitumor activity of epirubicin in specific cancer types.

Main Methods:

  • A phase I/II study involving 23 patients with advanced malignancies.
  • Escalating intravenous doses of epirubicin (100-120 mg/m2) administered every 3 weeks.

Related Experiment Videos

  • Assessment of toxicity, including mucositis, myelotoxicity, nausea, vomiting, alopecia, and cardiovascular effects.
  • Evaluation of treatment response using complete and partial response criteria.

    • Main Results:

    • Mucositis (grade II/III) occurred in 47% of courses at 120 mg/m2, compared to 15% at 115 mg/m2.
    • Leukopenia was the primary myelotoxicity, with a median white blood cell nadir of 1.9 x 10(9)/l.
    • Complete responses were observed in two patients (penile and gastric carcinoma), and partial responses in six (including breast cancer and sarcoma).
    • No renal, hepatic, or cardiac toxicity was noted; one fatal coronary thrombosis occurred.
    • Thrombophlebitis occurred in 4 patients, unrelated to dose.

    Conclusions:

    • Intermediate-dose epirubicin (up to 120 mg/m2) is generally well-tolerated in advanced malignancies.
    • Mucositis emerges as a dose-limiting toxicity at 120 mg/m2.
    • Epirubicin demonstrates promising preliminary activity in gastric cancer, breast cancer, and sarcomas.